Table 2.
Baseline demographics of patients with peptic ulcer bleeding who underwent Helicobacter pylori eradication therapy according to the time of eradication therapy initiation n (%)
| Eradication during hospitalization (n = 77) | Eradication at the OPC(n = 20) | P value | |
| Male | 59 (76.6) | 17 (85.0) | 0.550 |
| Age mean ± SD (yr) | 66.1 ± 13.9 | 59.5 ± 15.1 | 0.063 |
| Disease | 0.833 | ||
| BGU | 57 (74.0) | 16 (80) | |
| DU | 9 (11.7) | 1 (5.0) | |
| BGU and DU | 11 (14.3) | 3 (15.0) | |
| Eradication regimen | 0.191 | ||
| 7-d triple therapy1 | 60 (77.9) | 20 (100) | |
| 10-d triple therapy | 2 (2.6) | 0 | |
| 14-d triple therapy | 10 (13.0) | 0 | |
| Others | 5 (6.5) | 0 | |
| Smoking | 0.100 | ||
| Current | 22 (28.6) | 7 (35.0) | |
| Past | 5 (6.5) | 4 (20.0) | |
| Never | 50 (64.9) | 9 (45.0) | |
| Oral iron replacement during eradication therapy | 0.113 | ||
| Yes | 30 (39.0) | 4 (20.0) | |
| No | 47 (61.0) | 16 (80.0) |
1
Proton-pump inhibitor standard dose bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid. BGU: Benign gastric ulcer; DU: Duodenal ulcer; H. pylori: Helicobacter pylori; OPC: Outpatient clinic; PUB: Peptic ulcer bleeding.